Last edition
News about "plaque psoriasis"
Eli Lilly Reports Biomarker Changes With Taltz-Zepbound Combination
Eli Lilly has reported broader immune, inflammatory and metabolic biomarker changes with Taltz and Zepbound compared with Taltz alone in the TOGETHER-PsO trial.
Plaque Psoriasis | 12/10/2026 | By News Bureau
US FDA Accepts NDA under Priority Review for Takeda's Zasocitinib
The US Food and Drug Administration (FDA) has accepted Takeda’s New Drug Application (NDA) for zasocitinib under Priority Review (PR) for the treatment of moderate-to-severe plaque psoriasis, potentially redefining expectations for oral treatment.
Plaque Psoriasis | 15/09/2026 | By News Bureau
Biocon Receives Health Canada Approval for Yesintek Autoinjector Pen
Biocon has received Health Canada approval for the Yesintek autoinjector pen to treat plaque psoriasis, psoriatic arthritis, Crohn's Disease (CD) and Ulcerative Colitis (UC).
Plaque Psoriasis | 29/07/2026 | By News Bureau
EMA Backs Marketing Authorisation for Janssen's Icotyde in Plaque Psoriasis
CHMP backs marketing authorisation for icotrokinra to treat moderate-to-severe plaque psoriasis in adults and eligible adolescents, potentially making it the first oral IL-23-targeting therapy approved in the EU.
Plaque Psoriasis | 27/07/2026 | By News Bureau
Johnson & Johnson Secures FDA Approval for Icotyde, First Oral IL-23 Inhibitor for Psoriasis
FDA approves Johnson & Johnson’s Icotyde, a first-in-class oral IL-23 receptor antagonist, offering a once-daily treatment option for moderate-to-severe plaque psoriasis in adults and adolescents.
Plaque Psoriasis | 20/03/2026 | By News Bureau | 433
Innovent's PECONDLE Becomes China's First Approved IL-23p19 Antibody
Innovent has received NMPA approval for PECONDLE (picankibart injection), marking China’s first IL-23p19 monoclonal antibody to be cleared for treating moderate-to-severe plaque psoriasis in adults eligible for systemic therapy.
Plaque Psoriasis | 02/12/2025 | By Dineshwori | 560
Endo and Paladin Pharma to Commercialize Wynzora Cream in Canada
Wynzora® Cream is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis, including scalp psoriasis, in adults.
Plaque Psoriasis | 16/11/2024 | By Aishwarya | 578
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy